 |
| |
| Apr-12-19 | Initiated |
Guggenheim |
Buy |
|
|
| Mar-27-19 | Initiated |
Berenberg |
Buy |
$45 |
|
| Mar-15-19 | Initiated |
Raymond James |
Outperform |
|
|
| Sep-10-18 | Resumed |
BTIG Research |
Buy |
$56 |
|
| Mar-28-18 | Resumed |
Leerink Partners |
Outperform |
$36 |
|
| Mar-02-17 | Reiterated |
Wedbush |
Outperform |
$27 → $33 |
|
| Mar-02-17 | Initiated |
Instinet |
Neutral |
$21 |
|
| Oct-04-16 | Initiated |
Piper Jaffray |
Overweight |
|
|
| Dec-22-15 | Initiated |
Canaccord Genuity |
Buy |
$20 |
|
| Aug-05-15 | Reiterated |
MLV & Co |
Buy |
$22 → $29 |
|
| Feb-12-15 | Reiterated |
Oppenheimer |
Outperform |
$22 → $28 |
|
| Jan-28-15 | Reiterated |
MLV & Co |
Buy |
$18 → $22 |
|
| Jul-11-14 | Initiated |
Oppenheimer |
Outperform |
$22 |
|
|
|
| May-23-19 08:01AM | Xencor Appoints Jeremy Grunstein, Ph.D., as Vice President, Business Development Business Wire |
| May-15-19 12:14PM | Edited Transcript of XNCR earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents |
| May-10-19 09:23AM | Xencor Inc (XNCR) Q1 2019 Earnings Call Transcript Motley Fool +10.31% |
| May-09-19 04:43PM | Xencor: 1Q Earnings Snapshot Associated Press |
| 04:00PM | Xencor Reports First Quarter 2019 Financial Results Business Wire |
| May-08-19 04:01PM | Xencor to Present at Upcoming Investor Conferences Business Wire |
| May-06-19 08:01AM | Xencor Doses First Patient in Phase 1 Study of XmAb®23104 for the Treatment of Patients with Advanced Solid Tumors Business Wire |
| May-02-19 04:01PM | Xencor to Host First Quarter 2019 Financial Results Webcast and Conference Call on May 9, 2019 Business Wire |
| May-01-19 01:22PM | Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 24% Discount? Simply Wall St. |
| Apr-30-19 08:01AM | Xencor Announces Partial Clinical Hold Lifted on Phase 1 Study of XmAb®14045 Business Wire |
| Apr-29-19 09:55PM | Heres What Hedge Funds Think About Xencor Inc (XNCR) Insider Monkey |
| Apr-02-19 08:01AM | Xencor and Astellas Enter Collaboration for Novel Bispecific Antibody Program Business Wire |
| Apr-01-19 04:05PM | Xencor to Participate in Upcoming Investor Conferences Business Wire |
| 12:55PM | Why I Like Xencor, Inc. (NASDAQ:XNCR) Simply Wall St. |
| Mar-08-19 08:01AM | Xencor Announces Closing of Research Collaboration and License Agreement with Genentech Business Wire |
| Mar-06-19 07:00AM | New Research Coverage Highlights Clovis Oncology, Welltower, The Ultimate Software Group, Nielsen Holdings Plc, Xencor, and 21Vianet Group Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire |
| Mar-01-19 12:30PM | Is Xencor, Inc.s (NASDAQ:XNCR) CEO Paid Enough Relative To Peers? Simply Wall St. |
| 06:18AM | Edited Transcript of XNCR earnings conference call or presentation 25-Feb-19 9:30pm GMT Thomson Reuters StreetEvents |
| Feb-28-19 09:15AM | Too Much Talking, Not Enough Action Zacks |
| Feb-26-19 09:48PM | Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com |
| 09:11AM | Nielsen (NLSN) to Report Q4 Earnings: What's in the Offing? Zacks |
| Feb-25-19 09:05PM | Xencor Inc (XNCR) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 04:24PM | Xencor Reports Fourth Quarter and Full Year 2018 Financial Results PR Newswire |
| 02:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| 09:12AM | What's in Store for Booking Holdings' (BKNG) Q4 Earnings? Zacks |
| Feb-23-19 09:15AM | Strong Friday Close Secures a 9th Week in the Green Zacks |
| Feb-20-19 06:55AM | Xencor Announces Partial Clinical Hold on Phase 1 Study of XmAb14045 PR Newswire -6.54% |
| Feb-19-19 09:01AM | Xencor to Host Fourth Quarter and Full Year 2018 Financial Results Webcast and Conference Call on February 25, 2019 PR Newswire |
| Feb-07-19 09:01AM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| Feb-05-19 08:01AM | Xencor to Develop and Commercialize Novel IL-15 Immune Activating Cytokines with Genentech PR Newswire |
| Jan-28-19 07:35AM | Report: Developing Opportunities within ONEOK, Alaska Air Group, Comcast, Mack-Cali Realty, Vistra Energy, and Xencor Future Expectations, Projections Moving into 2019 GlobeNewswire |
| Jan-21-19 06:12AM | Have Insiders Been Selling Xencor, Inc. (NASDAQ:XNCR) Shares This Year? Simply Wall St. |
| Jan-07-19 08:01AM | Xencor Regains ex-U.S. Commercial Rights to XmAb®13676, CD20 x CD3 Bispecific Antibody PR Newswire |
| Dec-06-18 10:45AM | Is Xencor Inc (NASDAQ:XNCR) A Financially Strong Company? Simply Wall St. |
| Dec-04-18 07:35AM | Consolidated Research: 2018 Summary Expectations for Xencor, Cyclacel Pharmaceuticals, Amicus Therapeutics, Take-Two Interactive Software, CSG Systems International, and Vonage Fundamental Analysis, Key Performance Indications GlobeNewswire -6.28% |
| Dec-03-18 05:45PM | Xencor Presents Initial Data from Phase 1 Study of XmAb®14045 in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire |
| Nov-20-18 09:01AM | Xencor to Present at 30th Annual Piper Jaffray Healthcare Conference PR Newswire |
| Nov-08-18 09:01AM | Xencor Appoints Ellen G. Feigal, M.D., to Board of Directors PR Newswire |
| Nov-06-18 05:40PM | Edited Transcript of XNCR earnings conference call or presentation 5-Nov-18 9:30pm GMT Thomson Reuters StreetEvents +6.83% |
| 05:06AM | Xencor: 3Q Earnings Snapshot Associated Press |
| Nov-05-18 04:01PM | Xencor Reports Third Quarter 2018 Financial Results PR Newswire |
| Nov-01-18 09:01AM | Xencor to Present Initial Data from Phase 1 Study of XmAb®14045 Bispecific Antibody in Acute Myeloid Leukemia at the 2018 ASH Annual Meeting PR Newswire +15.59% |
| Oct-30-18 10:33AM | Earnings Preview: Xencor (XNCR) Q3 Earnings Expected to Decline Zacks |
| Oct-29-18 04:01PM | Xencor to Host Third Quarter 2018 Financial Results Webcast and Conference Call on November 5, 2018 PR Newswire -5.69% |
| Oct-25-18 08:50AM | Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.86% |
| Oct-05-18 08:01AM | Xencor Announces Topline Results from Phase 2 Study of XmAb®5871 in Systemic Lupus Erythematosus and Selection of Late-Breaking Abstract for Presentation at the 2018 ACR Annual Meeting PR Newswire |
| Sep-25-18 08:01AM | Xencor to Participate in Upcoming Investor Conferences PR Newswire -5.47% |
| Sep-18-18 06:32AM | 3 Top Healthcare Stocks to Buy Right Now Motley Fool |
| Aug-08-18 08:30AM | New Research Coverage Highlights Goldman Sachs BDC, PTC, Weingarten Realty Investors, Astronics, Xencor, and Chemours Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| Aug-07-18 04:50PM | This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation Investor's Business Daily +7.49% |
| Aug-06-18 05:45PM | Xencor (XNCR) Reports Q2 Loss, Misses Revenue Estimates Zacks |
| 04:41PM | Xencor: 2Q Earnings Snapshot Associated Press |
| 04:01PM | Xencor Reports Second Quarter 2018 Financial Results PR Newswire |
| 02:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| Aug-01-18 08:01AM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| Jul-30-18 08:01AM | Xencor to Host Second Quarter 2018 Financial Results Webcast and Conference Call on August 6, 2018 PR Newswire |
| Jul-18-18 06:00AM | Kodiak Sciences Appoints Bassil I. Dahiyat, Ph.D. Robert A. Profusek, J.D. and Richard S. Levy, M.D. to its Board of Directors PR Newswire |
| Jul-16-18 08:20AM | Today's Research Reports on Trending Tickers: REGENXBIO and Xencor ACCESSWIRE |
| Jul-12-18 04:00PM | Xencor Doses First Patient in Phase 1 Study of XmAb20717 Dual Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors PR Newswire |
| Jun-18-18 11:45AM | 3 Top Biotech Stocks to Buy Right Now Motley Fool |
| May-31-18 04:01PM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| May-09-18 03:56PM | Edited Transcript of XNCR earnings conference call or presentation 7-May-18 8:30pm GMT Thomson Reuters StreetEvents |
| May-07-18 04:19PM | Xencor: 1Q Earnings Snapshot Associated Press |
| 04:01PM | Xencor Reports First Quarter 2018 Financial Results PR Newswire |
| 12:30PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| May-04-18 07:55AM | Market Trends Toward New Normal in LRAD, Xencor, QuinStreet, Old Second, WesBanco, and Invitae Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire |
| May-02-18 08:00AM | Xencor to Present at Deutsche Bank 43rd Annual Health Care Conference PR Newswire |
| Apr-30-18 08:00AM | Xencor to Host First Quarter 2018 Financial Results Webcast and Conference Call on May 7, 2018 PR Newswire |
| Apr-18-18 09:00AM | Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting PR Newswire |
| Apr-11-18 06:31PM | What Do Analysts Think About Xencor Incs (NASDAQ:XNCR) Earnings Trajectory? Simply Wall St. |
| 01:46PM | Harry Boxers five biotech stocks to watch MarketWatch |
| Apr-04-18 09:15PM | 3 Top Biotech Stocks to Buy in April Motley Fool |
| Mar-30-18 03:21PM | Edited Transcript of XNCR earnings conference call or presentation 27-Feb-18 9:30pm GMT Thomson Reuters StreetEvents |
| Mar-21-18 08:00AM | Xencor to Present at 17th Annual Needham Healthcare Conference PR Newswire |
| Mar-20-18 07:44PM | Xencor Announces Pricing of Public Offering of Common Stock PR Newswire |
| Mar-19-18 04:09PM | Xencor, Inc. Announces Proposed Public Offering of Common Stock PR Newswire |
| Mar-03-18 04:43PM | What Do Investors Need To Know About Xencor Incs (NASDAQ:XNCR) Growth? Simply Wall St. |
| Mar-01-18 08:30AM | Consolidated Research: 2018 Summary Expectations for Sonic Automotive, Xencor, Gevo, OSI, Buckeye Partners, and Glatfelter Fundamental Analysis, Key Performance Indications GlobeNewswire |
| Feb-27-18 06:27PM | Xencor reports 4Q loss Associated Press |
| 04:01PM | Xencor Reports Fourth Quarter and Full Year 2017 Financial Results PR Newswire |
| 12:40PM | Xencor, Inc. to Host Earnings Call ACCESSWIRE |
| Feb-22-18 08:00AM | Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors PR Newswire +5.01% |
| Feb-20-18 08:00AM | Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018 PR Newswire |
| Feb-07-18 08:00AM | Xencor to Present at Upcoming Investor Conferences PR Newswire |
| Jan-05-18 08:00AM | Xencor Announces 2018 Priorities and Expected Milestones PR Newswire |
| 07:45AM | New Research: Key Drivers of Growth for Portola Pharmaceuticals, Kindred Healthcare, Interface, Apogee Enterprises, Sonic Automotive, and Xencor Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire |
| Jan-02-18 08:07AM | See what the IHS Markit Score report has to say about Xencor Inc. Markit |
| Dec-28-17 12:46PM | ETFs with exposure to Xencor, Inc. : December 28, 2017 Capital Cube |
| Dec-27-17 08:40AM | Xencor, Inc. :XNCR-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017 Capital Cube |
| Dec-19-17 08:00AM | Xencor Appoints Richard Ranieri to Board of Directors PR Newswire |
| Dec-14-17 02:48PM | Xencor, Inc. Value Analysis (NASDAQ:XNCR) : December 14, 2017 Capital Cube |
| Dec-13-17 07:42AM | Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : December 13, 2017 Capital Cube |
| Dec-05-17 08:00AM | Xencor Receives Milestone Payment from Amgen PR Newswire |
| Nov-27-17 08:07AM | Xencor, Inc. breached its 50 day moving average in a Bearish Manner : XNCR-US : November 27, 2017 Capital Cube |
| 08:05AM | See what the IHS Markit Score report has to say about Xencor Inc. Markit |
| Nov-15-17 08:04AM | See what the IHS Markit Score report has to say about Xencor Inc. Markit |
| Nov-13-17 02:16PM | Edited Transcript of XNCR earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents |
| Nov-10-17 08:16AM | See what the IHS Markit Score report has to say about Xencor Inc. Markit +5.36% |
| Nov-08-17 08:00AM | Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting PR Newswire |
| Nov-07-17 05:14PM | Xencor reports 3Q loss Associated Press |
|
|
|
|
| Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| STAFFORD JOHN S III | 10% Owner | May 02 | Buy | 29.87 | 14,611 | 436,407 | 5,077,359 | May 06 04:06 PM | | STAFFORD JOHN S III | 10% Owner | Mar 25 | Buy | 29.77 | 3,500 | 104,195 | 5,062,748 | Mar 26 04:32 PM | | STAFFORD JOHN S III | 10% Owner | Mar 22 | Buy | 29.96 | 2,000 | 59,920 | 5,059,248 | Mar 26 04:32 PM | | STAFFORD JOHN S III | 10% Owner | Mar 18 | Buy | 29.90 | 1,100 | 32,890 | 5,057,248 | Mar 19 05:04 PM | | STAFFORD JOHN S III | 10% Owner | Mar 15 | Buy | 29.02 | 38,300 | 1,111,466 | 5,056,148 | Mar 19 05:04 PM | | Foster Paul A | Chief Medical Officer | Sep 17 | Option Exercise | 11.05 | 40,000 | 442,000 | 44,952 | Sep 18 04:28 PM | | Foster Paul A | Chief Medical Officer | Sep 17 | Sale | 46.03 | 40,000 | 1,841,208 | 4,952 | Sep 18 04:28 PM | | STAFFORD JOHN S III | 10% Owner | Sep 14 | Sale | 48.05 | 1,000 | 48,054 | 5,017,848 | Sep 18 04:04 PM | | Foster Paul A | Chief Medical Officer | Aug 17 | Option Exercise | 11.05 | 3,659 | 40,432 | 8,611 | Aug 17 06:20 PM | | Foster Paul A | Chief Medical Officer | Aug 17 | Sale | 40.10 | 3,659 | 146,726 | 4,952 | Aug 17 06:20 PM | | Foster Paul A | Chief Medical Officer | Aug 16 | Option Exercise | 11.05 | 20,739 | 229,166 | 25,691 | Aug 16 07:31 PM | | Foster Paul A | Chief Medical Officer | Aug 16 | Sale | 41.10 | 20,739 | 852,373 | 4,952 | Aug 16 07:31 PM | | Foster Paul A | Chief Medical Officer | Aug 15 | Option Exercise | 11.05 | 106 | 1,171 | 5,058 | Aug 16 07:31 PM | | Foster Paul A | Chief Medical Officer | Aug 15 | Sale | 41.10 | 106 | 4,357 | 4,952 | Aug 16 07:31 PM | | Foster Paul A | Chief Medical Officer | Aug 14 | Option Exercise | 11.05 | 15,496 | 171,231 | 20,448 | Aug 16 07:31 PM | | Foster Paul A | Chief Medical Officer | Aug 14 | Sale | 41.11 | 15,496 | 636,980 | 4,952 | Aug 16 07:31 PM | | Baracchini Edgardo Jr | Chief Business Officer | Aug 13 | Option Exercise | 11.05 | 12,734 | 140,711 | 12,941 | Aug 13 07:59 PM | | Baracchini Edgardo Jr | Chief Business Officer | Aug 13 | Sale | 40.35 | 12,734 | 513,874 | 207 | Aug 13 07:59 PM | | Baracchini Edgardo Jr | Chief Business Officer | Aug 10 | Sale | 40.03 | 28,983 | 1,160,045 | 207 | Aug 13 07:59 PM | | Desjarlais John R | Sr. V.P., Research & CSO | Aug 10 | Sale | 40.03 | 14,867 | 595,092 | 88,098 | Aug 10 06:36 PM | | Desjarlais John R | Sr. V.P., Research & CSO | Aug 09 | Option Exercise | 4.25 | 35,000 | 148,750 | 123,098 | Aug 10 06:36 PM | | Baracchini Edgardo Jr | Chief Business Officer | Aug 09 | Option Exercise | 11.05 | 37,266 | 411,789 | 37,473 | Aug 13 07:59 PM | | Baracchini Edgardo Jr | Chief Business Officer | Aug 09 | Sale | 40.35 | 8,283 | 334,198 | 29,190 | Aug 13 07:59 PM | | Desjarlais John R | Sr. V.P., Research & CSO | Aug 09 | Sale | 40.61 | 20,133 | 817,629 | 102,965 | Aug 10 06:36 PM | | STAFFORD JOHN S III | 10% Owner | Jul 17 | Sale | 41.24 | 36,500 | 1,505,260 | 5,018,848 | Jul 17 04:08 PM | | STAFFORD JOHN S III | 10% Owner | Jul 16 | Sale | 40.67 | 26,888 | 1,093,535 | 5,055,348 | Jul 17 04:08 PM | | STAFFORD JOHN S III | 10% Owner | Jul 13 | Sale | 41.97 | 48,312 | 2,027,684 | 5,082,236 | Jul 17 04:08 PM | | STAFFORD JOHN S III | 10% Owner | Jul 12 | Sale | 39.55 | 58,000 | 2,293,900 | 5,130,548 | Jul 12 05:26 PM | | STAFFORD JOHN S III | 10% Owner | Jul 11 | Sale | 39.63 | 30,007 | 1,189,177 | 5,188,548 | Jul 12 05:26 PM | | STAFFORD JOHN S III | 10% Owner | Jul 10 | Sale | 39.89 | 50,293 | 2,006,188 | 5,218,555 | Jul 12 05:26 PM | | STAFFORD JOHN S III | 10% Owner | Jun 20 | Sale | 40.05 | 92,779 | 3,715,799 | 5,261,348 | Jun 20 04:28 PM | | STAFFORD JOHN S III | 10% Owner | Jun 19 | Sale | 39.77 | 103,454 | 4,114,366 | 5,354,127 | Jun 20 04:28 PM | | STAFFORD JOHN S III | 10% Owner | Jun 18 | Sale | 39.88 | 53,767 | 2,144,228 | 5,457,581 | Jun 20 04:28 PM | | Dahiyat Bassil I | President and CEO | Jun 15 | Option Exercise | 4.25 | 50,000 | 212,500 | 343,067 | Jun 15 08:11 PM | | Dahiyat Bassil I | President and CEO | Jun 15 | Sale | 40.51 | 50,000 | 2,025,690 | 293,067 | Jun 15 08:11 PM | | Kuch John J | Sr. Vice President & CFO | Jun 13 | Option Exercise | 4.25 | 35,853 | 152,375 | 92,482 | Jun 15 05:35 PM | | Kuch John J | Sr. Vice President & CFO | Jun 13 | Sale | 41.64 | 25,000 | 1,040,945 | 56,629 | Jun 15 05:35 PM |
|
|
|
|
|
|
